drugset
drugset / Trial / NCT01382901

Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)

NCT01382901 ↗

Phase 2 Completed 45 enrolled American Regent, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to evaluate the safety of 2 dosage regimens of Intravenous (IV) iron Ferric Carboxymaltose (FCM) in comparison to placebo in patients with Restless Legs Syndrome (RLS)

Timeline

Start
2006-03
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric carboxymaltose Other / unclassified — Intravenous

Indications

restless legs syndrome